3-((5-(4,6-dimethyl-2-(spiro[indene-1,4’-piperidin]-1‘-yl)pyrimidin-5-yl)-2-fluorobenzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid | 1544741-19-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 3-((5-(4,6-dimethyl-2-(spiro[indene-1,4’-piperidin]-1‘-yl)pyrimidin-5-yl)-2-fluorobenzyl)oxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid
• 英文别名: 8-[[5-(4,6-Dimethyl-2-spiro[indene-1,4'-piperidine]-1'-ylpyrimidin-5-yl)-2-fluorophenyl]methoxy]-9-azatricyclo[4.4.0.02,4]deca-1(10),6,8-triene-3-carboxylic acid
• CAS: 1544741-19-6
• 化学式: C₃₆H₃₃FN₄O₃
• 分子量: 588.681
• InChiKey: MRKLBJDUHDBMSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  44
• 可旋转键数：
  6
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  88.4
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• ANTIDIABETIC TRICYCLIC COMPOUNDS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140045746A1

  公开（公告）日：2014-02-13

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  化学结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，并可用于治疗、预防和抑制由G蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖和脂质异常，如混合或糖尿病性脂质异常、高脂血症、高胆固醇血症和高三酰甘油血症。
• US9527875B2
  申请人：——

  公开号：US9527875B2

  公开（公告）日：2016-12-27